Art. -Nr.: HY-14648A

Dexamethasone acetate

Name: Dexamethasone acetate
Brand: MedChemExpress
SKU: HY-14648A
Price: 55.00 USD
Availability: InStock
Rating: 5 (8 reviews)

(Synonyms: Dexamethasone 21-acetate; Hexadecadrol acetate)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.86%
CAS. Nr.: 1177-87-3
Formel: C₂₄H₃₁FO₆
Molecular Weight:434.50

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Dexamethasone acetate Chemical Structure

CAS. Nr.: 1177-87-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (3)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Glucocorticoid receptor^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	EC₅₀	4.5 μM Compound: Dexamethasone acetate	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]

In Vitro

Dexamethasone acetate (28.2 mg particles in 150 mL water; 37 days; 5 separate samples in 45 mL water; 26 days) encapsulated in PLGA-magnetite nanoparticles releases a total of 37.8% of particle weight as Dexamethasone equivalent over 37 days in aqueous solution, with 2% to 23% of particle weight released over 26 days in replicate experiments^[1].
Dexamethasone acetate (2 h; 48 h) loaded solid lipid nanoparticles exhibit an initial burst release of ~68% over 2 h followed by gradual release over 48 h in pH 7.4 phosphate buffer saline at 37°C^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

Magnetic targeting of PLGA-magnetite-Dexamethasone acetate nanoparticles (1-2 mg/mL; direct into RWM niche; two doses; total 1 hour magnetic field exposure) across the round window membrane in guinea pigs delivers a 2-fold enhancement of total Dex + Dex-Ac to cochlear tissues, reaching levels well above the therapeutic threshold^[1].
DA-NLCs (3 mg/kg; i.v.; single dose) deliver Dexamethasone acetate (DA) to inflamed pleural sites at concentrations 8.3 times higher than free DA, with a 10.6-fold larger AUC_0-t and prolonged residence time at the inflammatory site^[2].
DA-NLCs (7 mg/kg; i.v.; single dose) preferentially accumulate in mouse liver and lung tissues, achieving 1.8- to 2.6-fold larger AUC_0-ts than free DA, and prolong DA residence time in plasma^[2].
Dexamethasone acetate-loaded poly(ɛ-caprolactone) nanofibers (200 µg; intravitreous implantation via transscleral injection; single administration) exhibit excellent ocular biocompatibility and safety in the Rattus norvegicus eye, preserving retinal and choroidal structure and photoreceptor function over 10 days following intravitreous implantation^[3].
Dexamethasone acetate (10 mg/kg; i.v.; single dose) delivered via solid lipid nanoparticles exhibits remarkable lung-targeting in healthy Kunming mice, with a 17.8-fold higher lung AUC_0-t and 7.10 relative overall targeting efficiency compared to the free drug solution, while reducing uptake by liver and spleen macrophages^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1177-87-3
Appearance Solid
Molecular Weight 434.50
Formel C₂₄H₃₁FO₆
Color White to off-white
SMILES

C[C@@]1([C@@]2(O)C(COC(C)=O)=O)[C@](C[C@H]2C)([H])[C@@](CCC3=CC4=O)([H])[C@@](F)([C@]3(C=C4)C)[C@@H](O)C1
Synonyms

Dexamethasone 21-acetate; Hexadecadrol acetate
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (8)

All Histological Imaging/StainingBio/Physico-chemical AssayIHCELISAIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Adv Mater

Hydrolysis of 2D Nanosheets Reverses Rheumatoid Arthritis Through Anti-Inflammation and Osteogenesis. [Abstract]

2025 Feb;37(7):e2415543. PMID: 39726077
Phytother Res

Sappanone A Exerted Strong Anti-Inflammatory Effects in the Treatment of Atopic Dermatitis Through IL-21R-Mediated JAK1/STAT3 Pathway. [Abstract]

2025 Nov 14. PMID: 41236101

Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

The protein levels of IL-1β, IL-25, IL-33, and TSLP were detected by ELISA assays. HaCaT cells were treated with various concentrations of SA, Dexamethasone acetate (DEX, 50 μM), or left untreated under IL-4/IL-13/TNF-α stimulation.

Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]

The body weight in each group were measured at specific time points. The results showed that Dexamethasone acetate (DEX, 2.5 mg/kg; topical application) treatment further exacerbated the weight loss caused by MC903.
Free Radic Biol Med

Salvianolic acid B drives gluconeogenesis and peroxisomal redox remodeling in cardiac ischemia/reperfusion injury: A metabolism regulation by metabolite signal crosstalk. [Abstract]

2025 Mar 1:229:399-414. PMID: 39855316
ACS Appl Mater Interfaces

Spatiotemporal Circadian Oscillator Manipulation for Enhanced Ovarian Cancer Therapy Using a Versatile Nanoplatform. [Abstract]

2025 Jun 18;17(24):35023-35039. PMID: 40488667
J Ethnopharmacol

The anti-inflammatory potential of Cinnamomum camphora (L.) J.Presl essential oil in vitro and in vivo. [Abstract]

2021 Mar 1:267:113516. PMID: 33141054
J Agric Food Chem

Vitamin D 3 Metabolite-Enhanced Hepatic VDR-FXR Binding Attenuates Bile Acid Dysregulation-Induced Diarrhea in Weaned Piglets. [Abstract]

2026 Apr 22;74(15):12069-12086. PMID: 41952052
SSRN

2026 Mar 19.
MedComm Futur Med

2024 Jul 19.

Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: MedComm Futur Med. 2024 Jul 19.

Representative images of lung tissue stained with hematoxylin and eosin. The results showed that dexamethasone acetate (Dexm, 5 mg/kg; i.g.; once daily for 3 weeks) effectively alleviated the severe alveolar hemorrhage, edema, thickening of alveolar septa, and inflammatory cell infiltration induced by bleomycin instillation.

Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: MedComm Futur Med. 2024 Jul 19.

Dexamethasone acetate (Dexm, 5 mg/kg; i.g.; once daily for 3 weeks) effectively inhibited the bleomycin-induced elevation of serum levels of inflammatory cytokines—such as IL-1β, IL-6, and TNF-α—in mice with pulmonary fibrosis.

Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: MedComm Futur Med. 2024 Jul 19.

Representative immunohistochemical images of transforming growth factor β (TGF-β), α-smooth muscle actin (α-SMA), and collagen type I alpha 1 (Col1a1) in lung tissues. The results showed that Dexamethasone acetate (Dexm, 5 mg/kg; i.g.; once daily for 3 weeks) significantly inhibited the bleomycin-induced upregulation of TGF-β, α-SMA, and Col1a1 expression in mouse lung tissue.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (115.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3015 mL

11.5075 mL

23.0150 mL

5 mM

0.4603 mL

2.3015 mL

4.6030 mL

10 mM

0.2301 mL

1.1507 mL

2.3015 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related Animals and Diseases

Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Du X, et al. Magnetic targeted delivery of dexamethasone acetate across the round window membrane in guinea pigs. Otol Neurotol. 2013;34(1):41-47. [Content Brief]

[2]. Xu X, et al. Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv. 2011;18(7):485-492. [Content Brief]

[3]. Da Silva GR, et al. Ocular biocompatibility of dexamethasone acetate loaded poly(ɛ-caprolactone) nanofibers. Eur J Pharm Biopharm. 2019;142:20-30. [Content Brief]

[4]. Xiang QY, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res. 2007;30(4):519-525. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3015 mL	11.5075 mL	23.0150 mL	57.5374 mL
	5 mM	0.4603 mL	2.3015 mL	4.6030 mL	11.5075 mL
	10 mM	0.2301 mL	1.1507 mL	2.3015 mL	5.7537 mL
	15 mM	0.1534 mL	0.7672 mL	1.5343 mL	3.8358 mL
	20 mM	0.1151 mL	0.5754 mL	1.1507 mL	2.8769 mL
	25 mM	0.0921 mL	0.4603 mL	0.9206 mL	2.3015 mL
	30 mM	0.0767 mL	0.3836 mL	0.7672 mL	1.9179 mL
	40 mM	0.0575 mL	0.2877 mL	0.5754 mL	1.4384 mL
	50 mM	0.0460 mL	0.2301 mL	0.4603 mL	1.1507 mL
	60 mM	0.0384 mL	0.1918 mL	0.3836 mL	0.9590 mL
	80 mM	0.0288 mL	0.1438 mL	0.2877 mL	0.7192 mL
	100 mM	0.0230 mL	0.1151 mL	0.2301 mL	0.5754 mL

Bioz

Keywords

Dexamethasone acetate

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dexamethasone acetate

Publications Citing Use of MedChemExpress (MCE) Dexamethasone acetate